CLAIM CARD
The curated corpus lacks any randomized controlled trial of deuterium-depleted water (DDW) and is instead composed entirely of observational cohorts and preclinical models. All clinical evidence derives from uncontrolled designs in which DDW was administered alongside conventional cancer therapy (Somlyai 2025, Somlyai 2023, Boros 2021), making it impossible to isolate the independent contribution of deuterium depletion to the reported survival outcomes. Consequently, the headline conclusion that DDW "multiplies survival probability" rests on evidence that cannot meet conventional efficacy thresholds for causal inference.
Evidence grade: exploratory
Contradiction status: none
Publication: d8263221-9f0a-41ec-95ec-4711d2e47db6
Provenance: Derivation Web chain
Citation Support
source_1Somlyai 2025source_2Somlyai 2023source_3Boros 2021source_4Korchinsky 2024source_5Molnar 2021